Prescription medicine
Aceclidine Brand names: Vizz
Aceclidine (Vizz) is a prescription medicine with an FDA approval on record since 2025. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the aceclidine FDA label on DailyMed (effective January 14, 2026, LENZ Therapeutics, Inc.); the NDA 218585 record on Drugs@FDA; every aceclidine label on DailyMed.
Highlights of the record
FDA label of January 14, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageVIZZ is indicated for the treatment of presbyopia in adults.
Forms and strengths
- 14.66 mg/ml
Solution/ drops.
On the market
- Earliest approval on file
- July 31, 2025 Vizz, Lenz Therap; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- March 15, 2044 Vizz solution/drops; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 599 through July 30, 2026
What is aceclidine used for?
From the label: indications and usageVIZZ is indicated for the treatment of presbyopia in adults. VIZZ is a cholinergic agonist indicated for the treatment of presbyopia in adults ( 1 ).
FDA pharmacologic class: Cholinergic Receptor Agonist.
Source: FDA drug label (VIZZ), LENZ Therapeutics, Inc., effective January 14, 2026 (SPL set 7aed8024-ad30-44d6-8f3b-63338ad3ce52), via openFDA; the full label on DailyMed
Is there a generic for aceclidine (Vizz)?
No generic aceclidine is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 7 patents for Vizz solution/drops, the last expiring on March 15, 2044. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2025 earliest approval on file
- 2044 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for aceclidine?
The FDA Adverse Event Reporting System holds 599 reports that list aceclidine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 1 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other cholinergic receptor agonists
- the pharmacologic class, with prices and generics
- Aceclidine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other